Media

Regulatory Activities

Our first pre-IND application for the first generation of miR-22-3p antagomirs was positively reviewed by the FDA in 2015, setting the stage for the submission of full IND applications for Generation 2.5 of targeting antagomirs and agomirs to be submitted for early clinical program.